NR3C2 and metabolic dysfunction-associated steatotic liver disease: Of course, the validation of our findings in similar studies of spironolactone or other mineralocorticoid receptor antagonists in NAFLD patients or even in NAFLD-related transcriptome databases would have been of importance.